Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12379861 | 0.80 | TSHR (0.46) | SMN1; SMN2TSHR | |
| SCHEMBL70778 | 0.80 | TSHR (0.46) | SMN1; SMN2TSHR | |
| SCHEMBL1133592 | 0.80 | — | — | |
| SCHEMBL1474423 | 0.79 | TACR1 (0.40) | TACR1CYP2D6OPRL1TSHROPRM1 | |
| SCHEMBL13232146 | 0.77 | KDM4E (0.48) | SMN1; SMN2TSHR | |
| SCHEMBL65441 | 0.76 | ALDH1A1 (0.50) | SMN1; SMN2CYP2D6TSHRMEN1KMT2A | |
| SCHEMBL28738942 | 0.76 | — | — | |
| SCHEMBL65325 | 0.74 | ALDH1A1 (0.53) | SMN1; SMN2CYP2D6MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28912856 | 0.74 | ALDH1A1 (0.49) | SMN1; SMN2CYP2D6TSHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4391137 | 0.74 | ALDH1A1 (0.53) | SMN1; SMN2CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100166819-A1 | Transforming Growth Factor Modulators | BIOGEN IDEC MA INC. A CORPORATION | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166819-A1 | Transforming Growth Factor Modulators | ACVR1, TGFBR1, ACVRL1 | TACR1 160/4885SMN1; SMN2 4638/4885CYP2D6 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.